{"id":49553,"date":"2026-02-20T17:26:34","date_gmt":"2026-02-20T17:26:34","guid":{"rendered":"https:\/\/www.globalresearch.co.kr\/insight\/non-small-cell-lung-cancer-market-mordor\/"},"modified":"2026-09-25T11:10:27","modified_gmt":"2026-09-25T02:10:27","slug":"non-small-cell-lung-cancer-market-mordor","status":"publish","type":"post","link":"https:\/\/www.globalresearch.co.kr\/insight\/non-small-cell-lung-cancer-market-mordor\/","title":{"rendered":"\uc138\uacc4\uc758 \ube44\uc18c\uc138\ud3ec\ud3d0\uc554 (NSCLC) \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc810\uc720\uc728 \ubd84\uc11d &#8211; \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc804\ub9dd (2026\ub144 &#8211; 2031\ub144)"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/non-small-cell-lung-cancer-market_1660888084631_NSCLC.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/non-small-cell-lung-cancer-market-size-image-1771000385254.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-0\">1. \uc11c\ub860<\/p>\n<ul>\n<li class=\"toc-level-2\">1.1 \uc5f0\uad6c \uac00\uc815 \ubc0f \uc2dc\uc7a5 \uc815\uc758<\/li>\n<li class=\"toc-level-2\">1.2 \uc5f0\uad6c \ubc94\uc704<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-1\">2. \uc5f0\uad6c \ubc29\ubc95\ub860<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-2\">3. \uc694\uc57d<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-3\">4. \uc2dc\uc7a5 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">4.1 \uc2dc\uc7a5 \uac1c\uc694<\/li>\n<li class=\"toc-level-2\">4.2 \uc2dc\uc7a5 \ub3d9\uc778\n<ul>\n<li class=\"toc-level-3\">4.2.1 1\ucc28 \uc804\uc774\uc131 \ud658\uacbd\uc5d0\uc11c \uccb4\ud06c\ud3ec\uc778\ud2b8 \uc5b5\uc81c\uc81c\uc758 \uc9c0\ubc30\ub825<\/li>\n<li class=\"toc-level-3\">4.2.2 \uc808\uc81c \uac00\ub2a5\ud55c \ucd08\uae30 \ube44\uc18c\uc138\ud3ec\ud3d0\uc554(NSCLC)\uc5d0\uc11c EGFR\/ALK \ud45c\uc801 \uce58\ub8cc\uc81c\uc758 \ube60\ub978 \ucc44\ud0dd<\/li>\n<li class=\"toc-level-3\">4.2.3 \uc561\uccb4 \uc0dd\uac80 \ub3d9\ubc18 \uc9c4\ub2e8 \ucc44\ud0dd<\/li>\n<li class=\"toc-level-3\">4.2.4 \ubc29\uc0ac\uc131 \uc758\uc57d\ud488 \ud30c\uc774\ud504\ub77c\uc778\uc758 \ud601\uc2e0<\/li>\n<li class=\"toc-level-3\">4.2.5 AI \uae30\ubc18 \uc784\uc0c1 \uc124\uacc4 \ubc0f FDA \uc2b9\uc778 \uac00\uc18d\ud654<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.3 \uc2dc\uc7a5 \uc81c\uc57d \uc694\uc778\n<ul>\n<li class=\"toc-level-3\">4.3.1 \uc720\ub7fd\uc758 \uac00\uaca9 \uc0c1\ud55c\uc81c \ubc0f HTA(\ubcf4\uac74\uc758\ub8cc\uae30\uc220\ud3c9\uac00) \ubc18\ubc1c<\/li>\n<li class=\"toc-level-3\">4.3.2 \uc2e0\ud765 \uc544\uc2dc\uc544 \uc9c0\uc5ed\uc758 \uc9c4\ub2e8 \ubc14\uc774\uc624\ub9c8\ucee4 \ud14c\uc2a4\ud2b8 \uc5ed\ub7c9 \uaca9\ucc28<\/li>\n<li class=\"toc-level-3\">4.3.3 PD-(L)1 \uacc4\uc5f4 \ud3ec\ud654 \ubc0f \uc9c0\ubd88\uc790 \ub9ac\ubca0\uc774\ud2b8 \uc555\ubc15<\/li>\n<li class=\"toc-level-3\">4.3.4 ADC \ud398\uc774\ub85c\ub4dc \uc81c\uc870 \ubcd1\ubaa9 \ud604\uc0c1<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.4 \uac00\uce58 \/ \uacf5\uae09\ub9dd \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">4.5 \uaddc\uc81c \ud658\uacbd<\/li>\n<li class=\"toc-level-2\">4.6 \uae30\uc220 \uc804\ub9dd<\/li>\n<li class=\"toc-level-2\">4.7 \ud3ec\ud130\uc758 5\uac00\uc9c0 \uacbd\uc7c1 \uc694\uc778\n<ul>\n<li class=\"toc-level-3\">4.7.1 \uc2e0\uaddc \uc9c4\uc785\uc790\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.7.2 \uacf5\uae09\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.7.3 \uad6c\ub9e4\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.7.4 \ub300\uccb4\uc7ac\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.7.5 \uacbd\uc7c1 \uac15\ub3c4<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-4\">5. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21 (\uac00\uce58)<\/p>\n<ul>\n<li class=\"toc-level-2\">5.1 \uc870\uc9c1\ud559\uc801 \ubd84\ub958\n<ul>\n<li class=\"toc-level-3\">5.1.1 \uc120\uc554<\/li>\n<li class=\"toc-level-3\">5.1.2 \ud3b8\ud3c9\uc0c1\ud53c\uc138\ud3ec\uc554<\/li>\n<li class=\"toc-level-3\">5.1.3 \ub300\uc138\ud3ec\uc554<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.2 \uce58\ub8cc \uc591\uc2dd\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.2.1 \uc218\uc220<\/li>\n<li class=\"toc-level-3\">5.2.2 \ubc29\uc0ac\uc120 \uce58\ub8cc<\/li>\n<li class=\"toc-level-3\">5.2.3 \ud654\ud559\uc694\ubc95<\/li>\n<li class=\"toc-level-3\">5.2.4 \ud45c\uc801 \uce58\ub8cc<\/li>\n<li class=\"toc-level-3\">5.2.5 \uba74\uc5ed\uc694\ubc95<\/li>\n<li class=\"toc-level-3\">5.2.6 \ubc29\uc0ac\uc131 \uc758\uc57d\ud488<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.3 \uc57d\ubb3c \ub4f1\uae09\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.3.1 EGFR TKIs<\/li>\n<li class=\"toc-level-3\">5.3.2 ALK\/ROS1\/RET \uc5b5\uc81c\uc81c<\/li>\n<li class=\"toc-level-3\">5.3.3 PD-1 \/ PD-L1 \uc5b5\uc81c\uc81c<\/li>\n<li class=\"toc-level-3\">5.3.4 CTLA-4 &amp; LAG-3 \uc5b5\uc81c\uc81c<\/li>\n<li class=\"toc-level-3\">5.3.5 \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4 (ADC)<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.4 \uc9c0\uc5ed\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.4.1 \ubd81\ubbf8<\/li>\n<li class=\"toc-level-4\">5.4.1.1 \ubbf8\uad6d<\/li>\n<li class=\"toc-level-4\">5.4.1.2 \uce90\ub098\ub2e4<\/li>\n<li class=\"toc-level-4\">5.4.1.3 \uba55\uc2dc\ucf54<\/li>\n<li class=\"toc-level-3\">5.4.2 \uc720\ub7fd<\/li>\n<li class=\"toc-level-4\">5.4.2.1 \ub3c5\uc77c<\/li>\n<li class=\"toc-level-4\">5.4.2.2 \uc601\uad6d<\/li>\n<li class=\"toc-level-4\">5.4.2.3 \ud504\ub791\uc2a4<\/li>\n<li class=\"toc-level-4\">5.4.2.4 \uc2a4\ud398\uc778<\/li>\n<li class=\"toc-level-4\">5.4.2.5 \uc774\ud0c8\ub9ac\uc544<\/li>\n<li class=\"toc-level-4\">5.4.2.6 \uae30\ud0c0 \uc720\ub7fd<\/li>\n<li class=\"toc-level-3\">5.4.3 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<\/li>\n<li class=\"toc-level-4\">5.4.3.1 \uc911\uad6d<\/li>\n<li class=\"toc-level-4\">5.4.3.2 \uc778\ub3c4<\/li>\n<li class=\"toc-level-4\">5.4.3.3 \uc77c\ubcf8<\/li>\n<li class=\"toc-level-4\">5.4.3.4 \ub300\ud55c\ubbfc\uad6d<\/li>\n<li class=\"toc-level-4\">5.4.3.5 \ud638\uc8fc<\/li>\n<li class=\"toc-level-4\">5.4.3.6 \uae30\ud0c0 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<\/li>\n<li class=\"toc-level-3\">5.4.4 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.4.4.1 GCC<\/li>\n<li class=\"toc-level-4\">5.4.4.2 \ub0a8\uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.4.4.3 \uae30\ud0c0 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-3\">5.4.5 \ub0a8\ubbf8<\/li>\n<li class=\"toc-level-4\">5.4.5.1 \ube0c\ub77c\uc9c8<\/li>\n<li class=\"toc-level-4\">5.4.5.2 \uc544\ub974\ud5e8\ud2f0\ub098<\/li>\n<li class=\"toc-level-4\">5.4.5.3 \uae30\ud0c0 \ub0a8\ubbf8<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-5\">6. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">6.1 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4<\/li>\n<li class=\"toc-level-2\">6.2 \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">6.3 \uae30\uc5c5 \ud504\ub85c\ud544 (\uae00\ub85c\ubc8c \uac1c\uc694, \uc2dc\uc7a5 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uc7ac\ubb34 \uc815\ubcf4(\uac00\ub2a5\ud55c \uacbd\uc6b0), \uc804\ub7b5 \uc815\ubcf4, \uc8fc\uc694 \uae30\uc5c5 \uc2dc\uc7a5 \uc21c\uc704\/\uc810\uc720\uc728, \uc81c\ud488 \ubc0f \uc11c\ube44\uc2a4, \ucd5c\uadfc \uac1c\ubc1c \ud3ec\ud568)\n<ul>\n<li class=\"toc-level-3\">6.3.1 AstraZeneca<\/li>\n<li class=\"toc-level-3\">6.3.2 Merck &amp; Co.<\/li>\n<li class=\"toc-level-3\">6.3.3 F. Hoffmann-La Roche<\/li>\n<li class=\"toc-level-3\">6.3.4 Bristol Myers Squibb<\/li>\n<li class=\"toc-level-3\">6.3.5 Novartis<\/li>\n<li class=\"toc-level-3\">6.3.6 Pfizer<\/li>\n<li class=\"toc-level-3\">6.3.7 Eli Lilly<\/li>\n<li class=\"toc-level-3\">6.3.8 Amgen<\/li>\n<li class=\"toc-level-3\">6.3.9 BeiGene<\/li>\n<li class=\"toc-level-3\">6.3.10 Takeda<\/li>\n<li class=\"toc-level-3\">6.3.11 Regeneron<\/li>\n<li class=\"toc-level-3\">6.3.12 Sanofi<\/li>\n<li class=\"toc-level-3\">6.3.13 Daiichi Sankyo<\/li>\n<li class=\"toc-level-3\">6.3.14 Johnson &amp; Johnson<\/li>\n<li class=\"toc-level-3\">6.3.15 Boehringer Ingelheim<\/li>\n<li class=\"toc-level-3\">6.3.16 Innovent Biologics<\/li>\n<li class=\"toc-level-3\">6.3.17 Exelixis<\/li>\n<li class=\"toc-level-3\">6.3.18 Mirati Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.19 Blueprint Medicines<\/li>\n<li class=\"toc-level-3\">6.3.20 Zai Lab<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-6\">7. \uc2dc\uc7a5 \uae30\ud68c \ubc0f \ubbf8\ub798 \uc804\ub9dd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ube44\uc18c\uc138\ud3ec\ud3d0\uc554(NSCLC) \uce58\ub8cc\uc81c \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \ubd84\uc11d \ubcf4\uace0\uc11c (2031\ub144)<\/p>\n<p># \uc2dc\uc7a5 \uac1c\uc694 \ubc0f \uc8fc\uc694 \uc9c0\ud45c<\/p>\n<p>\ube44\uc18c\uc138\ud3ec\ud3d0\uc554(NSCLC) \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 2026\ub144 241\uc5b5 7\ucc9c\ub9cc \ub2ec\ub7ec\uc5d0\uc11c 2031\ub144 388\uc5b5 5\ucc9c\ub9cc \ub2ec\ub7ec\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, \uc608\uce21 \uae30\uac04(2026-2031\ub144) \ub3d9\uc548 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR) 9.96%\ub97c \uae30\ub85d\ud560 \uc804\ub9dd\uc785\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc131\uc7a5\uc740 \ud68d\uae30\uc801\uc778 \uba74\uc5ed\ud56d\uc554\uc81c\uc5d0 \ub300\ud55c \uc218\uc694 \uc99d\uac00, \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADC)\uc758 \uc2e0\uc18d\ud55c FDA \uc2b9\uc778, \ubc29\uc0ac\uc131\uc758\uc57d\ud488 \uc815\ubc00 \ud45c\uc801\ud654\uc758 \uafb8\uc900\ud55c \ubc1c\uc804 \ub4f1\uc5d0 \uc758\ud574 \uac00\uc18d\ud654\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc81c\uc57d \uc120\ub450 \uae30\uc5c5\ub4e4\uc774 \uc778\uacf5\uc9c0\ub2a5(AI) \uae30\ubc18 \ubc14\uc774\uc624\ub9c8\ucee4 \ud50c\ub7ab\ud3fc\uc73c\ub85c \uc804\ud658\ud558\uace0 \uc561\uccb4 \uc0dd\uac80 \ub3d9\ubc18 \uc9c4\ub2e8\uc774 \ud45c\uc801 \uce58\ub8cc\uc81c\uc758 \uc7a0\uc7ac \ud658\uc790\uad70\uc744 \ud655\ub300\ud568\uc5d0 \ub530\ub77c \uacbd\uc7c1 \uac15\ub3c4 \ub610\ud55c \uc2ec\ud654\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \uc2dc\uc7a5 \uc9c0\ud45c:<br \/>\n*   \uc5f0\uad6c \uae30\uac04: 2020\ub144 &#8211; 2031\ub144<br \/>\n*   2026\ub144 \uc2dc\uc7a5 \uaddc\ubaa8: 241\uc5b5 7\ucc9c\ub9cc \ub2ec\ub7ec<br \/>\n*   2031\ub144 \uc2dc\uc7a5 \uaddc\ubaa8: 388\uc5b5 5\ucc9c\ub9cc \ub2ec\ub7ec<br \/>\n*   \uc131\uc7a5\ub960 (2026-2031): 9.96% CAGR<br \/>\n*   \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc2dc\uc7a5: \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<br \/>\n*   \uac00\uc7a5 \ud070 \uc2dc\uc7a5: \ubd81\ubbf8<br \/>\n*   \uc2dc\uc7a5 \uc9d1\uc911\ub3c4: \uc911\uac04<\/p>\n<p># \uc2dc\uc7a5 \uc131\uc7a5 \ub3d9\ub825 (Driver Impact Analysis)<\/p>\n<p>NSCLC \uc2dc\uc7a5\uc758 \uc131\uc7a5\uc744 \uacac\uc778\ud558\ub294 \uc8fc\uc694 \ub3d9\ub825\uc740 \ub2e4\uc74c\uacfc \uac19\uc2b5\ub2c8\ub2e4.<\/p>\n<p>1.  \uc804\uc774\uc131 1\ucc28 \uce58\ub8cc \ud658\uacbd\uc5d0\uc11c\uc758 \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c \uc6b0\uc704 (Check-point inhibitor dominance in 1L metastatic setting):<br \/>\n    *   CAGR \uae30\uc5ec\ub3c4: 2.80%<br \/>\n    *   \uc9c0\ub9ac\uc801 \uad00\ub828\uc131: \uc804 \uc138\uacc4\uc801, \ud2b9\ud788 \ubd81\ubbf8 \ubc0f \uc720\ub7fd\uc5d0\uc11c \uac15\uc138<br \/>\n    *   \uc601\ud5a5 \uc2dc\uae30: \uc911\uae30 (2-4\ub144)<br \/>\n    *   \uc138\ubd80 \ub0b4\uc6a9: \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c \uc694\ubc95\uc740 \uc8fc\uc694 \uc2dc\uc7a5\uc5d0\uc11c \uc804\uc774\uc131 \uc9c8\ud658\uc758 1\ucc28 \uce58\ub8cc\uc5d0\uc11c \ubc31\uae08 \uae30\ubc18 \uc774\uc911 \uc694\ubc95\uc744 \ub300\uccb4\ud558\uba70 \uc784\uc0c1 \uac00\uc774\ub4dc\ub77c\uc778\uacfc \ubcf4\ud5d8 \uc815\ucc45\uc744 \uc7ac\ud3b8\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc808\uc81c \uac00\ub2a5\ud55c 2\uae30-3A\uae30 NSCLC\uc5d0 \ub300\ud55c \ud3a8\ube0c\ub864\ub9ac\uc8fc\ub9d9(pembrolizumab)\uacfc \ud654\ud559\uc694\ubc95 \ubcd1\uc6a9\uc758 \uc911\uad6d \uad6d\uac00\uc758\uc57d\ud488\uad00\ub9ac\uad6d(NMPA) \uc2b9\uc778\uc740 \uc774 \uacc4\uc5f4\uc774 \uc644\uce58 \ubaa9\uc801 \uce58\ub8cc \ud658\uacbd\uc73c\ub85c \ud655\uc7a5\ub418\uace0 \uc788\uc74c\uc744 \ubcf4\uc5ec\uc90d\ub2c8\ub2e4. \uc774\ubcf4\ub124\uc2dc\ub9d9(ivonescimab)\uacfc \uac19\uc740 \uc2e0\ud765 \uc774\uc911\ud2b9\uc774\ud56d\uccb4\ub294 PD-L1 \uace0\ubc1c\ud604 \uc885\uc591\uc5d0\uc11c \ud3a8\ube0c\ub864\ub9ac\uc8fc\ub9d9 \ub300\ube44 \uc9c8\ubcd1 \uc9c4\ud589 \uc704\ud5d8\uc744 49% \uac10\uc18c\uc2dc\ud0a4\ub294 \ub4f1 \uae30\uc874 \uc2dc\uc7a5 \uc810\uc720\uc728\uc744 \uc7a0\uc2dd\ud560 \uac00\ub2a5\uc131\uc744 \uc2dc\uc0ac\ud569\ub2c8\ub2e4.<\/p>\n<p>2.  \uc808\uc81c \uac00\ub2a5\ud55c \ucd08\uae30 \ub2e8\uacc4 NSCLC\uc5d0\uc11c EGFR\/ALK \ud45c\uc801 \uce58\ub8cc\uc81c\uc758 \ube60\ub978 \ucc44\ud0dd (Rapid uptake of EGFR\/ALK targeted therapies in resectable early-stage NSCLC):<br \/>\n    *   CAGR \uae30\uc5ec\ub3c4: 2.10%<br \/>\n    *   \uc9c0\ub9ac\uc801 \uad00\ub828\uc131: \uc804 \uc138\uacc4\uc801, \ud2b9\ud788 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591\uc5d0\uc11c \uac15\uc138<br \/>\n    *   \uc601\ud5a5 \uc2dc\uae30: \ub2e8\uae30 (\u2264 2\ub144)<br \/>\n    *   \uc138\ubd80 \ub0b4\uc6a9: \uc808\uc81c \ubd88\uac00\ub2a5\ud55c 3\uae30 EGFR \ubcc0\uc774 \uc9c8\ud658\uc5d0\uc11c \uc624\uc2dc\uba38\ud2f0\ub2d9(osimertinib)\uc758 39.1\uac1c\uc6d4 \uc911\uc559 \ubb34\uc9c4\ud589 \uc0dd\uc874 \uae30\uac04\uc740 \ud45c\uc801 \uce58\ub8cc\ub97c \uce58\ub8cc \uc5f0\uc18d\uccb4\uc758 \ucd08\uae30 \ub2e8\uacc4\ub85c \uc804\ud658\ud558\uba70 \ud45c\uc900\uc744 \uc7ac\uc815\uc758\ud588\uc2b5\ub2c8\ub2e4. \uc544\ubbf8\ubc18\ud0c0\ub9d9(amivantamab)\uacfc \ub77c\uc81c\ub974\ud2f0\ub2d9(lazertinib) \ubcd1\uc6a9 \uc694\ubc95\uc740 \uc624\uc2dc\uba38\ud2f0\ub2d9 \ub2e8\ub3c5 \uc694\ubc95 \ub300\ube44 \uc0ac\ub9dd \uc704\ud5d8\uc744 25% \uac10\uc18c\uc2dc\ucf1c 1\ucc28 \ubcf4\uc870 \uce58\ub8cc \ud658\uacbd\uc5d0\uc11c\uc758 \ub300\uccb4 \uc18d\ub3c4\ub97c \uac00\uc18d\ud654\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>3.  \uc561\uccb4 \uc0dd\uac80 \ub3d9\ubc18 \uc9c4\ub2e8 \ucc44\ud0dd (Liquid-biopsy companion diagnostics adoption):<br \/>\n    *   CAGR \uae30\uc5ec\ub3c4: 1.40%<br \/>\n    *   \uc9c0\ub9ac\uc801 \uad00\ub828\uc131: \ubd81\ubbf8 \ubc0f \uc720\ub7fd, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591\uc73c\ub85c \ud655\ub300 \uc911<br \/>\n    *   \uc601\ud5a5 \uc2dc\uae30: \uc911\uae30 (2-4\ub144)<br \/>\n    *   \uc138\ubd80 \ub0b4\uc6a9: \ub85c\uc288(Roche)\uc758 AI \uae30\ubc18 TROP2 \ubd84\uc11d\ubc95\uc774 FDA\ub85c\ubd80\ud130 \ud601\uc2e0 \uc758\ub8cc\uae30\uae30\ub85c \uc9c0\uc815\ub41c \uac83\uc740 \uc804\uc0b0 \ubcd1\ub9ac\ud559\uc774 \ubc14\uc774\uc624\ub9c8\ucee4 \uc815\ud655\ub3c4\ub97c \ub192\uc774\uace0 \ub2e4\ud1a0\ud3ec\ud0c0\ub9d9 \ub370\ub8e9\uc2a4\ud14c\uce78(datopotamab deruxtecan)\uacfc \uac19\uc740 ADC\uc758 \uc801\uaca9\uc131\uc744 \ud655\ub300\ud558\ub294 \ubc29\uc2dd\uc744 \ubcf4\uc5ec\uc90d\ub2c8\ub2e4. \uc21c\ud658 \uc885\uc591 DNA(ctDNA) \ubd84\uc11d\uc740 \uc601\uc0c1 \uac80\uc0ac\ubcf4\ub2e4 \uba87 \ub2ec \uc55e\uc11c \ub0b4\uc131 \ubcc0\uc774\ub97c \uac10\uc9c0\ud558\uc5ec \uce58\ub8cc \uc911 \uc804\ud658 \uc804\ub7b5\uc744 \uac00\ub2a5\ud558\uac8c \ud569\ub2c8\ub2e4.<\/p>\n<p>4.  \ubc29\uc0ac\uc131\uc758\uc57d\ud488 \ud30c\uc774\ud504\ub77c\uc778 \ud601\uc2e0 (Radiopharmaceutical pipeline breakthroughs):<br \/>\n    *   CAGR \uae30\uc5ec\ub3c4: 1.90%<br \/>\n    *   \uc9c0\ub9ac\uc801 \uad00\ub828\uc131: \uc804 \uc138\uacc4\uc801, \ubbf8\uad6d \ubc0f \uc720\ub7fd\uc5d0 \uc81c\uc870 \ud5c8\ube0c<br \/>\n    *   \uc601\ud5a5 \uc2dc\uae30: \uc7a5\uae30 (\u2265 4\ub144)<br \/>\n    *   \uc138\ubd80 \ub0b4\uc6a9: \ub178\ubc14\ud2f0\uc2a4(Novartis)\uc758 \ub9c8\ub9ac\uc544\ub098 \uc628\ucf5c\ub85c\uc9c0(Mariana Oncology) 10\uc5b5 \ub2ec\ub7ec \uc778\uc218\ub294 \ud3d0 \uc545\uc131 \uc885\uc591\uc5d0 \ub300\ud55c \ud45c\uc801 \uc54c\ud30c \uce58\ub8cc \uc790\uc0b0\uc5d0 \ub300\ud55c \ud22c\uc790\uc790 \uc2e0\ub8b0\ub97c \ub4b7\ubc1b\uce68\ud569\ub2c8\ub2e4. \uc77c\ub77c\uc774 \ub9b4\ub9ac(Eli Lilly)\uc758 \uc545\ud2f0\uc2a4 \uc628\ucf5c\ub85c\uc9c0(Aktis Oncology)\uc640\uc758 11\uc5b5 \ub2ec\ub7ec \uc81c\ud734\ub294 \ubbf8\ub2c8\ub2e8\ubc31\uc9c8 \uc720\ub3c4 \ubc29\uc0ac\uc131\uc758\uc57d\ud488 \uc804\ub2ec \ubd84\uc57c\uc758 \uc720\uc0ac\ud55c \ubaa8\uba58\ud140\uc744 \uac15\uc870\ud569\ub2c8\ub2e4.<\/p>\n<p>5.  AI \uae30\ubc18 \uc784\uc0c1 \uc124\uacc4 \ubc0f FDA \uc2b9\uc778 \uac00\uc18d\ud654 (AI-guided trial design &#038; faster FDA approvals):<br \/>\n    *   CAGR \uae30\uc5ec\ub3c4: 1.20%<br \/>\n    *   \uc9c0\ub9ac\uc801 \uad00\ub828\uc131: \uc804 \uc138\uacc4\uc801, \ubbf8\uad6d \uc8fc\ub3c4<br \/>\n    *   \uc601\ud5a5 \uc2dc\uae30: \ub2e8\uae30 (\u2264 2\ub144)<br \/>\n    *   \uc138\ubd80 \ub0b4\uc6a9: AI\ub294 \uc784\uc0c1 \uc2dc\ud5d8 \uc124\uacc4 \ubc0f \ub370\uc774\ud130 \ubd84\uc11d\uc744 \ucd5c\uc801\ud654\ud558\uc5ec \uc2e0\uc57d \uac1c\ubc1c \ud504\ub85c\uc138\uc2a4\ub97c \uac00\uc18d\ud654\ud558\uace0 FDA \uc2b9\uc778 \uc2dc\uac04\uc744 \ub2e8\ucd95\ud558\ub294 \ub370 \uae30\uc5ec\ud569\ub2c8\ub2e4. \uc774\ub294 \ud601\uc2e0\uc801\uc778 \uce58\ub8cc\ubc95\uc758 \uc2dc\uc7a5 \ucd9c\uc2dc\ub97c \ucd09\uc9c4\ud558\uc5ec \uc2dc\uc7a5 \uc131\uc7a5\uc5d0 \uae0d\uc815\uc801\uc778 \uc601\ud5a5\uc744 \ubbf8\uce69\ub2c8\ub2e4.<\/p>\n<p># \uc2dc\uc7a5 \uc81c\uc57d \uc694\uc778 (Restraint Impact Analysis)<\/p>\n<p>NSCLC \uc2dc\uc7a5\uc758 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc8fc\uc694 \uc81c\uc57d \uc694\uc778\uc740 \ub2e4\uc74c\uacfc \uac19\uc2b5\ub2c8\ub2e4.<\/p>\n<p>1.  \uc720\ub7fd\uc758 \uac00\uaca9 \uc0c1\ud55c\uc81c \ubc0f HTA \uc555\ub825 (Price caps &#038; HTA push-backs in Europe):<br \/>\n    *   CAGR \uc601\ud5a5: -1.80%<br \/>\n    *   \uc9c0\ub9ac\uc801 \uad00\ub828\uc131: \uc720\ub7fd 27\uac1c\uad6d<br \/>\n    *   \uc601\ud5a5 \uc2dc\uae30: \uc911\uae30 (2-4\ub144)<br \/>\n    *   \uc138\ubd80 \ub0b4\uc6a9: \uc720\ub7fd \ubcf4\uac74 \uae30\uc220 \ud3c9\uac00(HTA) \uae30\uad00\ub4e4\uc740 \ube44\uc6a9-\ud6a8\uacfc\uc131 \uae30\uc900\uc744 \uac15\ud654\ud558\uc5ec \ud504\ub9ac\ubbf8\uc5c4 \uba74\uc5ed\ud56d\uc554\uc81c \uac00\uaca9 \ucc45\uc815\uc5d0 \uc5b4\ub824\uc6c0\uc744 \uc8fc\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ub3c5\uc77c\uc758 IQWiG\ub294 \ud45c\uc900 \uce58\ub8cc \ub300\ube44 \ucda9\ubd84\ud55c \uc0dd\uc874\uc728 \uac1c\uc120\uc774 \uc5c6\ub2e4\ub294 \uc774\uc720\ub85c \uc5ec\ub7ec \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c \ubcd1\uc6a9 \uc694\ubc95\uc744 \uac70\ubd80\ud558\uc5ec, \uc81c\uc870\uc0ac\ub4e4\uc774 \uc704\ud5d8 \uacf5\uc720 \uc81c\ub3c4\ub97c \ucc44\ud0dd\ud558\ub3c4\ub85d \uac15\uc81c\ud588\uc2b5\ub2c8\ub2e4.<\/p>\n<p>2.  \uc2e0\ud765 \uc544\uc2dc\uc544 \uc9c0\uc5ed\uc758 \uc9c4\ub2e8 \ubc14\uc774\uc624\ub9c8\ucee4 \uac80\uc0ac \uc5ed\ub7c9 \uaca9\ucc28 (Diagnostic biomarker testing capacity gaps in emerging Asia):<br \/>\n    *   CAGR \uc601\ud5a5: -1.20%<br \/>\n    *   \uc9c0\ub9ac\uc801 \uad00\ub828\uc131: \uc778\ub3c4 \ubc0f \ub3d9\ub0a8\uc544\uc2dc\uc544<br \/>\n    *   \uc601\ud5a5 \uc2dc\uae30: \ub2e8\uae30 (\u2264 2\ub144)<br \/>\n    *   \uc138\ubd80 \ub0b4\uc6a9: \ubd84\uc790 \ubcd1\ub9ac\ud559 \uc790\uc6d0\uc740 \uc5ec\uc804\ud788 \ub3c4\uc2dc \uc911\uc2ec\uc5d0 \uc9d1\uc911\ub418\uc5b4 \uc788\uc5b4, \uce58\ub8cc\ube44\uc758 60% \uc774\uc0c1\uc744 \uc790\ube44\ub85c \ubd80\ub2f4\ud558\ub294 \uc778\ub3c4 \ub18d\ucd0c \uc9c0\uc5ed\uc5d0\uc11c\ub294 \uce58\ub8cc \uc2dc\uc791\uc774 \uc9c0\uc5f0\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc81c\ud55c\ub41c \ucc28\uc138\ub300 \uc5fc\uae30\uc11c\uc5f4 \ubd84\uc11d(NGS) \ud50c\ub7ab\ud3fc\uc740 EGFR, ALK, ROS1 \uac80\uc0ac\uc758 \ucc44\ud0dd\uc744 \uc81c\ud55c\ud558\uc5ec \uc815\ubc00 \uce58\ub8cc\uc81c\uc758 \ubcf4\uae09\uc744 \uc9c1\uc811\uc801\uc73c\ub85c \ub2a6\ucd94\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>3.  PD-(L)1 \uacc4\uc5f4 \ud3ec\ud654 \ubc0f \ubcf4\ud5d8\uc0ac \ub9ac\ubca0\uc774\ud2b8 \uc555\ubc15 (PD-(L)1 class saturation &#038; payer rebate squeeze):<br \/>\n    *   CAGR \uc601\ud5a5: -1.50%<br \/>\n    *   \uc9c0\ub9ac\uc801 \uad00\ub828\uc131: \uc804 \uc138\uacc4 \uc131\uc219 \uc2dc\uc7a5<br \/>\n    *   \uc601\ud5a5 \uc2dc\uae30: \uc911\uae30 (2-4\ub144)<br \/>\n    *   \uc138\ubd80 \ub0b4\uc6a9: PD-1\/PD-L1 \uc5b5\uc81c\uc81c \uc2dc\uc7a5\uc740 \uc774\ubbf8 \ud3ec\ud654 \uc0c1\ud0dc\uc5d0 \uac00\uae4c\uc6cc\uc9c0\uace0 \uc788\uc73c\uba70, \uacbd\uc7c1 \uc2ec\ud654\ub85c \uc778\ud574 \ubcf4\ud5d8\uc0ac\ub4e4\uc758 \ub9ac\ubca0\uc774\ud2b8 \uc555\ubc15\uc774 \uc99d\uac00\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc774\ub294 \uc81c\uc57d \ud68c\uc0ac\ub4e4\uc758 \uc218\uc775\uc131\uc5d0 \ubd80\uc815\uc801\uc778 \uc601\ud5a5\uc744 \ubbf8\uccd0 \uc2dc\uc7a5 \uc131\uc7a5\uc744 \ub454\ud654\uc2dc\ud0ac \uc218 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>4.  ADC \ud398\uc774\ub85c\ub4dc \uc81c\uc870 \ubcd1\ubaa9 \ud604\uc0c1 (Manufacturing bottlenecks for ADC payloads):<br \/>\n    *   CAGR \uc601\ud5a5: -0.90%<br \/>\n    *   \uc9c0\ub9ac\uc801 \uad00\ub828\uc131: \uc804 \uc138\uacc4 \uacf5\uae09\ub9dd<br \/>\n    *   \uc601\ud5a5 \uc2dc\uae30: \ub2e8\uae30 (\u2264 2\ub144)<br \/>\n    *   \uc138\ubd80 \ub0b4\uc6a9: \ubcf5\uc7a1\ud55c ADC \ud398\uc774\ub85c\ub4dc\uc758 \uc81c\uc870\uc5d0\ub294 \uace0\ub3c4\uc758 \uae30\uc220\uacfc \uc804\ubb38 \uc2dc\uc124\uc774 \ud544\uc694\ud558\uba70, \uc774\ub294 \uacf5\uae09\ub9dd \ubcd1\ubaa9 \ud604\uc0c1\uc744 \ucd08\ub798\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc81c\uc57d\uc740 ADC\uc758 \uc0dd\uc0b0 \ubc0f \uc2dc\uc7a5 \uacf5\uae09\uc5d0 \uc601\ud5a5\uc744 \ubbf8 \ubbf8\uccd0 \uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc81c\ud55c\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p># \uc138\uadf8\uba3c\ud2b8 \ubd84\uc11d<\/p>\n<p>1. \uc870\uc9c1\ud559\uc801 \ubd84\ub958 (By Histology): \uc120\uc554\uc885(Adenocarcinoma)\uc774 \ud45c\uc801 \uce58\ub8cc \ud601\uc2e0 \uc8fc\ub3c4<br \/>\n*   \uc120\uc554\uc885(Adenocarcinoma): 2025\ub144 NSCLC \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 45.10%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \ube44\ud761\uc5f0\uc790\ub4e4 \uc0ac\uc774\uc5d0\uc11c \ub192\uc740 \uc720\ubcd1\ub960\uacfc EGFR \ubc0f ALK \uc5b5\uc81c\uc81c\uc5d0 \ub300\ud55c \ubc18\uc751\uc131 \ub355\ubd84\uc785\ub2c8\ub2e4. \uc624\uc2dc\uba38\ud2f0\ub2d9\uc774 \uc808\uc81c \ubd88\uac00\ub2a5\ud55c 3\uae30 \uc9c8\ud658\uc73c\ub85c \ud655\ub300\ub418\uba74\uc11c \uce58\ub8cc \ub300\uc0c1 \uc120\uc554\uc885 \ud658\uc790\uad70\uc774 \uc99d\uac00\ud588\uc73c\uba70, \uc774\uc911\ud2b9\uc774\ud56d\uccb4\uc640 ADC\ub294 \ucd94\uac00\uc801\uc778 \uac1c\uc120\uc744 \uc57d\uc18d\ud569\ub2c8\ub2e4.<br \/>\n*   \ud3b8\ud3c9\uc138\ud3ec\uc554\uc885(Squamous Cell Carcinoma): \uc791\uc6a9 \uac00\ub2a5\ud55c \ub3cc\uc5f0\ubcc0\uc774\uac00 \uc801\uc5b4 \uc81c\ud55c\uc801\uc774\uc5c8\uc73c\ub098, FGFR \uc5b5\uc81c\uc81c\uc640 \ud654\ud559-\uba74\uc5ed\uce58\ub8cc \ubcd1\uc6a9 \uc694\ubc95\uc73c\ub85c \uc0dd\uc874\uc728\uc774 \uc5f0\uc7a5\ub418\uba74\uc11c \ud61c\ud0dd\uc744 \ubcf4\uae30 \uc2dc\uc791\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ub300\uc138\ud3ec\uc554\uc885(Large-cell carcinoma): \ucd08\uae30 \uc810\uc720\uc728\uc740 \uc791\uc9c0\ub9cc, AI \uac15\ud654 \ubcd1\ub9ac\ud559\uc774 \uc544\ud615 \uc778\uc2dd\uc744 \uac1c\uc120\ud558\uace0 \uc784\uc0c1 \uc2dc\ud5d8 \ub4f1\ub85d\uc744 \uc99d\uac00\uc2dc\ud0a4\uba74\uc11c 2031\ub144\uae4c\uc9c0 11.05%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<\/p>\n<p>2. \uce58\ub8cc \uc591\uc2dd (By Treatment Modality): \uba74\uc5ed\uce58\ub8cc \ub9ac\ub354\uc2ed, \ubc29\uc0ac\uc131\uc758\uc57d\ud488\uc758 \ud601\uc2e0\uc801 \ub3c4\uc804<br \/>\n*   \uba74\uc5ed\uce58\ub8cc(Immunotherapy): 2025\ub144 \ub9e4\ucd9c \uc810\uc720\uc728 37.25%\ub97c \uc720\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uad11\ubc94\uc704\ud55c \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c \ucc44\ud0dd\uacfc PD-L1 \uace0\ubc1c\ud604 \uc885\uc591\uc5d0\uc11c \ubc18\uc751\uc744 \uc2ec\ud654\uc2dc\ud0a4\ub294 \uc774\uc911\ud2b9\uc774\ud56d\uccb4\uc758 \ud655\uc7a5\uc774 \ub4b7\ubc1b\uce68\ub418\uc5c8\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ubc29\uc0ac\uc131\uc758\uc57d\ud488(Radiopharmaceuticals): \ud604\uc7ac \ub9e4\ucd9c\uc758 3% \ubbf8\ub9cc\uc744 \ucc28\uc9c0\ud558\uc9c0\ub9cc, \uc885\uc591 \uc120\ud0dd\uc801 \ubc29\uc0ac\uc120\uc744 \uc804\ub2ec\ud558\ub294 \uc54c\ud30c \ubc29\ucd9c \uc811\ud569\uccb4\uc758 \uac15\uc810\uc5d0 \ud798\uc785\uc5b4 12.03%\uc758 CAGR\ub85c \uae09\uaca9\ud788 \uc131\uc7a5\ud560 \uc900\ube44\uac00 \ub418\uc5b4 \uc788\uc2b5\ub2c8\ub2e4. \ub3d9\ubc18 \uc9c4\ub2e8\uc774 \uc131\uc219\ud558\uace0 \ub3d9\uc704\uc6d0\uc18c \uacf5\uae09 \uc81c\uc57d\uc774 \uc644\ud654\ub418\uba74 \uc2dc\uc7a5 \uaddc\ubaa8\uac00 \ud06c\uac8c \ud655\ub300\ub420 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uc218\uc220(Surgery): \uc548\uc815\uc801\uc778 \ucc44\ud0dd\ub960\uc744 \uc720\uc9c0\ud558\uace0 \uc788\uc73c\ub098, \uc218\uc220 \uac00\ub2a5\uc131\uc744 \ub192\uc774\ub294 \uc2e0\ubcf4\uc870 \uba74\uc5ed\ud56d\uc554\uc81c \ubcd1\uc6a9 \uc694\ubc95\uc758 \ud61c\ud0dd\uc744 \ubc1b\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>3. \uc57d\ubb3c \ubd84\ub958 (By Drug Class): PD-1\/PD-L1 \uc6b0\uc704, ADC \ud601\uc2e0\uc73c\ub85c \ub3c4\uc804\ubc1b\ub2e4<br \/>\n*   PD-1\/PD-L1 \uc5b5\uc81c\uc81c: 2025\ub144 NSCLC \uc2dc\uc7a5\uc758 40.85%\ub97c \ucc28\uc9c0\ud558\uba70 \uc804\uc774\uc131 \ubc0f \ubcf4\uc870 \uce58\ub8cc \ud658\uacbd \ubaa8\ub450\uc5d0\uc11c \ud45c\uc900 \uce58\ub8cc\uc758 \ud575\uc2ec\uc785\ub2c8\ub2e4. \uc774\uc911\ud2b9\uc774\ud56d\uccb4\uac00 \uc6b0\uc218\ud55c \ubb34\uc9c4\ud589 \uc0dd\uc874\uc728\uc744 \ubcf4\uace0\ud558\uace0 CTLA-4 \ubc0f LAG-3 \uc81c\uc81c\uac00 \ubcd1\uc6a9 \uc694\ubc95\uc5d0 \ud569\ub958\ud558\uba74\uc11c \uacbd\uc7c1\uc774 \uc2ec\ud654\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADCs): 11.74%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub978 \uc131\uc7a5 \uada4\ub3c4\ub97c \uae30\ub85d\ud588\uc2b5\ub2c8\ub2e4. \ub2e4\ud1a0\ud3ec\ud0c0\ub9d9 \ub370\ub8e9\uc2a4\ud14c\uce78(datopotamab deruxtecan)\uc774 \uc911\uc99d \uc804\ucc98\ub9ac EGFR \ubcc0\uc774 \uc9c8\ud658\uc5d0\uc11c 42.7%\uc758 \uac1d\uad00\uc801 \ubc18\uc751\ub960\uc744 \ub2ec\uc131\ud558\uba70 \uc120\ub450\ub97c \ub2ec\ub9ac\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   ALK\/ROS1\/RET \uc5b5\uc81c\uc81c: \ud0c8\ub809\ud2b8\ub809\ud2f0\ub2d9(taletrectinib)\uc774 ROS1 \uc591\uc131 \uce58\ub8cc \uacbd\ud5d8\uc774 \uc5c6\ub294 \ud658\uc790\uc5d0\uc11c 90%\uc758 \ubc18\uc751\ub960\uc744 \ub2ec\uc131\ud558\ub294 \ub4f1 \ud2c8\uc0c8 \ubd84\uc790 \uc544\ud615\uc744 \uacc4\uc18d\ud574\uc11c \uacf5\ub7b5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   EGFR TKI: \ucd08\uae30 \uce58\ub8cc \ud658\uacbd\uc73c\ub85c \ud655\ub300\ub418\uace0 \uc788\uc73c\uba70, \ub0b4\uc131 \uac1c\uc120 \ubcd1\uc6a9 \uc694\ubc95\uc774 \ud3c9\uac00 \uc911\uc785\ub2c8\ub2e4.<\/p>\n<p># \uc9c0\uc5ed \ubd84\uc11d (Geography Analysis)<\/p>\n<p>*   \ubd81\ubbf8: 2025\ub144 NSCLC \uc2dc\uc7a5\uc758 41.95%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uc2e0\uc18d\ud55c \uaddc\uc81c \uc2b9\uc778, \uc120\uc9c4 \ubcf4\ud5d8 \uc801\uc6a9 \ubc94\uc704, \uc9d1\uc911\ub41c \uc5f0\uad6c \uc778\ud504\ub77c \ub355\ubd84\uc785\ub2c8\ub2e4. 2024\ub144\uc5d0\ub9cc \ub450 \uac1c\uc758 ADC\uc640 \ud558\ub098\uc758 \uc774\uc911\ud2b9\uc774\ud56d\uccb4\ub97c \ud3ec\ud568\ud55c 6\uac1c\uc758 \uc0c8\ub85c\uc6b4 \ud3d0\uc554 \uce58\ub8cc\uc81c\uac00 FDA \uc2b9\uc778\uc744 \ubc1b\uc73c\uba70 \uaddc\uc81c \ubbfc\ucca9\uc131\uc744 \ubcf4\uc5ec\uc8fc\uc5c8\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591: 2031\ub144\uae4c\uc9c0 12.23%\uc758 CAGR\uc744 \uae30\ub85d\ud558\uba70 NSCLC \uc2dc\uc7a5\uc5d0\uc11c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc9c0\uc5ed\uc774 \ub420 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc758\ub8cc\ube44 \uc9c0\ucd9c \uc99d\uac00, \uc9c4\ub2e8 \uc801\uc6a9 \ubc94\uc704 \uac1c\uc120, \ub192\uc740 EGFR \ubcc0\uc774 \uc720\ubcd1\ub960\uc774 \uc218\uc694\ub97c \ub4b7\ubc1b\uce68\ud569\ub2c8\ub2e4. \uc911\uad6d\uc740 \uc218\uc785 \uba74\uc5ed\uad00\ubb38\uc5b5\uc81c\uc81c \ubc0f ADC\uc758 \ud604\uc9c0 \uc2b9\uc778\uc744 \uac00\uc18d\ud654\ud558\uc5ec FDA \uacb0\uc815\uacfc\uc758 \uc2dc\ucc28\ub97c \uc904\uc600\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc720\ub7fd: \uc815\uad50\ud55c \ubd84\uc790 \uc758\ud559 \ucc44\ud0dd\uacfc \uac00\uaca9 \ud1b5\uc81c \uc815\ucc45\uc744 \uacb0\ud569\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc5c4\uaca9\ud55c HTA \ud3c9\uac00\ub294 \uc2dc\ud310 \ud6c4 \uc99d\uac70\ub97c \uc218\uc9d1\ud558\uba74\uc11c \uc870\uae30 \uc811\uadfc\uc744 \ud5c8\uc6a9\ud558\ub294 \uad00\ub9ac\ud615 \uc9c4\uc785 \uacc4\uc57d(managed-entry agreements)\uc744 \ub9cc\ub4e4\uc5b4\ub0c5\ub2c8\ub2e4.<br \/>\n*   \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8: \ucd08\uae30 \ub2e8\uacc4\uc758 \uae30\ud68c\ub97c \ub098\ud0c0\ub0c5\ub2c8\ub2e4. \ube0c\ub77c\uc9c8\uc758 \uacf5\uacf5 \uc885\uc591\ud559 \ud30c\ud2b8\ub108\uc2ed \ubc0f \uac78\ud504 \uad6d\uac00\uc758 \uc554 \uc13c\ud130 \ud655\uc7a5\uacfc \uac19\uc740 \uc774\ub2c8\uc154\ud2f0\ube0c\ub294 \uc778\ud504\ub77c\uac00 \uc131\uc219\ud568\uc5d0 \ub530\ub77c \uc810\uc9c4\uc801\uc73c\ub85c \uc9c0\uc5ed NSCLC \uc2dc\uc7a5\uc744 \ud655\ub300\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p># \uacbd\uc7c1 \ud658\uacbd<\/p>\n<p>NSCLC \uc2dc\uc7a5\uc740 \uc18c\uc218\uc758 \uae00\ub85c\ubc8c \uc81c\uc57d \ub300\uae30\uc5c5\uc774 \uc0c1\ub2f9\ud558\uc9c0\ub9cc \uc555\ub3c4\uc801\uc774\uc9c0 \uc54a\uc740 \uc810\uc720\uc728\uc744 \ucc28\uc9c0\ud558\ub294 \uc911\uac04 \uc815\ub3c4\uc758 \uc9d1\uc911\ub3c4\ub97c \ubcf4\uc785\ub2c8\ub2e4. \ub192\uc740 \uac1c\ubc1c \ube44\uc6a9, \ubcf5\uc7a1\ud55c \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \uc81c\uc870, \uc804\ubb38\ud654\ub41c \uc720\ud1b5 \ucc44\ub110\uc774 \uac15\ub825\ud55c \uc9c4\uc785 \uc7a5\ubcbd\uc744 \ud615\uc131\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \uacbd\uc7c1 \uc804\ub7b5:<br \/>\n*   \uc804\ub7b5\uc801 \uc81c\ud734: \ube0c\ub9ac\uc2a4\ud1a8 \ub9c8\uc774\uc5b4\uc2a4 \uc2a4\ud045(Bristol Myers Squibb)\uacfc \ubc14\uc774\uc624\uc5d4\ud14d(BioNTech)\uc758 \uc774\uc911\ud2b9\uc774\ud56d\uccb4 BNT327\uc5d0 \ub300\ud55c \uae00\ub85c\ubc8c \ud30c\ud2b8\ub108\uc2ed\uc740 \uc0c8\ub85c\uc6b4 \ud50c\ub7ab\ud3fc\uc5d0 \uc811\uadfc\ud558\ub294 \ub300\ud615 \uc81c\uc57d\uc0ac\uc758 \ubbfc\ucca9\uc131\uc744 \ubcf4\uc5ec\uc90d\ub2c8\ub2e4.<br \/>\n*   \uc815\ubc00 \uc9c4\ub2e8 \ubc0f \uce58\ub8cc \uc0dd\ud0dc\uacc4: \ub3d9\ubc18 \uc9c4\ub2e8\uacfc \uc57d\ubb3c\uc744 \ubb36\uc744 \uc218 \uc788\ub294 \uae30\uc874 \uae30\uc5c5\uc5d0 \uc720\ub9ac\ud55c \uc804\ud658 \ube44\uc6a9\uc744 \ubc1c\uc0dd\uc2dc\ud0b5\ub2c8\ub2e4.<br \/>\n*   AI \uae30\ubc18 \ubc1c\uacac: \ub85c\uc288(Roche)\uc758 \uc804\uc0b0 \ubcd1\ub9ac\ud559 \ud22c\uc790\ub294 \uc774\ub7ec\ud55c \ubcc0\ud654\ub97c \uc798 \ubcf4\uc5ec\uc90d\ub2c8\ub2e4.<br \/>\n*   \uc218\uc9c1 \ud1b5\ud569: \uc120\ub3c4 \uae30\uc5c5\ub4e4\uc740 \ubc29\uc0ac\uc131\uc758\uc57d\ud488 \ubd84\uc57c\uc5d0\uc11c \uacf5\uae09\ub9dd \uc2dc\ub108\uc9c0\ub97c \ud655\ubcf4\ud558\uae30 \uc704\ud574 \uc218\uc9c1 \ud1b5\ud569\uc744 \uac15\ud654\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ub178\ubc14\ud2f0\uc2a4(Novartis)\ub294 2024\ub144 \uc774\ud6c4 \ubc29\uc0ac\uc131 \ub9ac\uac04\ub4dc \uc778\uc218\uc5d0 17\uc5b5 \ub2ec\ub7ec \uc774\uc0c1\uc744 \ud22c\uc790\ud558\uc5ec \ub3d9\uc704\uc6d0\uc18c \uc81c\uc870 \uae30\ubc18\uc744 \ud655\ub300\ud588\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \uc2dc\uc7a5 \ucc38\uc5ec \uae30\uc5c5:<br \/>\n*   F. Hoffmann-La Roche Ltd.<br \/>\n*   Bristol-Myers Squibb Company<br \/>\n*   Pfizer Inc.<br \/>\n*   AstraZeneca<br \/>\n*   Novartis AG<\/p>\n<p>\ucd5c\uadfc \uc0b0\uc5c5 \ub3d9\ud5a5:<br \/>\n*   2025\ub144 6\uc6d4: \ud0c8\ub809\ud2b8\ub809\ud2f0\ub2d9(Taletrectinib)\uc774 ROS1 \uc591\uc131 NSCLC\uc5d0 \ub300\ud55c FDA \uc2b9\uc778\uc744 \ubc1b\uc544 1\ucc28 \uce58\ub8cc \ud658\uc790\uc5d0\uc11c 90%\uc758 \uac1d\uad00\uc801 \ubc18\uc751\ub960\uc744 \ub2ec\uc131\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2025\ub144 6\uc6d4: \ube0c\ub9ac\uc2a4\ud1a8 \ub9c8\uc774\uc5b4\uc2a4 \uc2a4\ud045(Bristol Myers Squibb)\uacfc \ubc14\uc774\uc624\uc5d4\ud14d(BioNTech)\uc774 \uc774\uc911\ud2b9\uc774\ud56d\uccb4 BNT327\uc5d0 \ub300\ud55c \uae00\ub85c\ubc8c \ud30c\ud2b8\ub108\uc2ed\uc744 \uc2dc\uc791\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2025\ub144 5\uc6d4: \ud154\ub9ac\uc18c\ud22c\uc8fc\ub9d9 \ubca0\ub3c4\ud2f4(Telisotuzumab vedotin)\uc774 c-Met \uace0\ubc1c\ud604 NSCLC\uc5d0 \ub300\ud55c FDA \uac00\uc18d \uc2b9\uc778\uc744 \ud68d\ub4dd\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2025\ub144 4\uc6d4: \uc885\uac8c\ub974\ud2f0\ub2d9(Zongertinib)\uc774 HER2 \ubcc0\uc774 NSCLC\uc5d0 \ub300\ud55c FDA \uc6b0\uc120 \uc2ec\uc0ac\uc5d0 \uc9c4\uc785\ud588\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uacb0\ub860\uc801\uc73c\ub85c, \ube44\uc18c\uc138\ud3ec\ud3d0\uc554 \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 \ud601\uc2e0\uc801\uc778 \uce58\ub8cc\ubc95\uc758 \ub4f1\uc7a5\uacfc \uc9c4\ub2e8 \uae30\uc220\uc758 \ubc1c\uc804\uc73c\ub85c \uc778\ud574 \uc5ed\ub3d9\uc801\uc778 \uc131\uc7a5\uc744 \uc9c0\uc18d\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \uac00\uaca9 \uaddc\uc81c, \uc9c4\ub2e8 \uc5ed\ub7c9 \uaca9\ucc28, \uacf5\uae09\ub9dd \uc81c\uc57d \ub4f1\uc740 \uc2dc\uc7a5 \uc131\uc7a5\uc5d0 \ub3c4\uc804 \uacfc\uc81c\ub85c \uc791\uc6a9\ud560 \uac83\uc785\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 2019\ub144\ubd80\ud130 2030\ub144\uae4c\uc9c0 17\uac1c\uad6d \ube44\uc18c\uc138\ud3ec\ud3d0\uc554(NSCLC) \uc2dc\uc7a5\uc744 \ubd84\uc11d\ud558\uba70, \uc120\uc554, \ud3b8\ud3c9\uc0c1\ud53c\uc138\ud3ec\uc554, \ub300\uc138\ud3ec\uc554 \ub4f1 \ud2b9\uc815 \uc870\uc9c1\ud559\uc801 \uc720\ud615\uc5d0 \ub300\ud55c \ucc98\ubc29 \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc744 \ub2e4\ub8f9\ub2c8\ub2e4. \ubd84\uc11d \ubc94\uc704\uc5d0\ub294 \uc218\uc220 \ubcf4\uc870 \uc57d\ubb3c, \ud654\ud559\uc694\ubc95, \ud45c\uc801 \uce58\ub8cc, \uba74\uc5ed\uc694\ubc95, \ubc29\uc0ac\uc131 \uc758\uc57d\ud488, \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADC) \ub4f1\uc774 \ud3ec\ud568\ub418\uba70, \uc18c\uc138\ud3ec\ud3d0\uc554 \uad00\ub828 \uce58\ub8cc\ubc95\uc740 \uc81c\uc678\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \ub3d9\uc778 \ubc0f \uc81c\uc57d \uc694\uc778:<br \/>\n\uc2dc\uc7a5\uc758 \uc8fc\uc694 \ub3d9\uc778\uc73c\ub85c\ub294 1\ucc28 \uc804\uc774\uc131 \ud658\uacbd\uc5d0\uc11c\uc758 \uccb4\ud06c\ud3ec\uc778\ud2b8 \uc5b5\uc81c\uc81c \uc9c0\ubc30\ub825, \uc808\uc81c \uac00\ub2a5\ud55c \ucd08\uae30 NSCLC\uc5d0\uc11c EGFR\/ALK \ud45c\uc801 \uce58\ub8cc\uc81c\uc758 \ube60\ub978 \ucc44\ud0dd, \uc561\uccb4 \uc0dd\uac80 \ub3d9\ubc18 \uc9c4\ub2e8(CDx)\uc758 \ud655\uc0b0, \ubc29\uc0ac\uc131 \uc758\uc57d\ud488 \ud30c\uc774\ud504\ub77c\uc778\uc758 \ud601\uc2e0, \uadf8\ub9ac\uace0 AI \uae30\ubc18 \uc784\uc0c1 \uc124\uacc4 \ubc0f FDA \uc2b9\uc778 \uac00\uc18d\ud654 \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n\ubc18\uba74, \uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc694\uc778\uc73c\ub85c\ub294 \uc720\ub7fd \ub0b4 \uac00\uaca9 \uc0c1\ud55c\uc81c \ubc0f \ubcf4\uac74\uae30\uc220\ud3c9\uac00(HTA)\uc758 \uc555\ubc15, \uc544\uc2dc\uc544 \uc2e0\ud765\uad6d\uc758 \uc9c4\ub2e8 \ubc14\uc774\uc624\ub9c8\ucee4 \ud14c\uc2a4\ud2b8 \uc5ed\ub7c9 \ubd80\uc871, PD-(L)1 \uacc4\uc5f4 \uc57d\ubb3c\uc758 \uc2dc\uc7a5 \ud3ec\ud654 \ubc0f \uc9c0\ubd88\uc790 \ub9ac\ubca0\uc774\ud2b8 \uc555\ubc15, \uadf8\ub9ac\uace0 ADC \ud398\uc774\ub85c\ub4dc\uc758 \uc81c\uc870 \ubcd1\ubaa9 \ud604\uc0c1 \ub4f1\uc774 \uc9c0\ubaa9\ub429\ub2c8\ub2e4. \ud2b9\ud788 \uc720\ub7fd\uc758 \uc5c4\uaca9\ud55c HTA \uae30\uc900\uc740 \uc2dc\uc7a5\uc758 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR)\uc744 \uc57d 1.8% \uac10\uc18c\uc2dc\ud0a4\ub294 \uac83\uc73c\ub85c \ucd94\uc815\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uc138\ubd84\ud654 \ubc0f \uc608\uce21:<br \/>\n\ubcf8 \ubcf4\uace0\uc11c\ub294 \uc2dc\uc7a5\uc744 \uc870\uc9c1\ud559\uc801 \uc720\ud615(\uc120\uc554, \ud3b8\ud3c9\uc0c1\ud53c\uc138\ud3ec\uc554, \ub300\uc138\ud3ec\uc554), \uce58\ub8cc \uc591\uc2dd(\uc218\uc220, \ubc29\uc0ac\uc120 \uce58\ub8cc, \ud654\ud559\uc694\ubc95, \ud45c\uc801 \uce58\ub8cc, \uba74\uc5ed\uc694\ubc95, \ubc29\uc0ac\uc131 \uc758\uc57d\ud488), \uc57d\ubb3c \uacc4\uc5f4(EGFR TKI, ALK\/ROS1\/RET \uc5b5\uc81c\uc81c, PD-1\/PD-L1 \uc5b5\uc81c\uc81c, CTLA-4 &#038; LAG-3 \uc5b5\uc81c\uc81c, ADC), \uadf8\ub9ac\uace0 \uc9c0\uc5ed(\ubd81\ubbf8, \uc720\ub7fd, \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591, \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8)\ubcc4\ub85c \uc138\ubd84\ud654\ud558\uc5ec \ubd84\uc11d\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21\uc5d0 \ub530\ub974\uba74, \ube44\uc18c\uc138\ud3ec\ud3d0\uc554 \uc2dc\uc7a5\uc740 2026\ub144 241.7\uc5b5 \ub2ec\ub7ec\uc5d0 \ub3c4\ub2ec\ud588\uc73c\uba70, 9.96%\uc758 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR)\ub85c \uc9c0\uc18d\uc801\uc778 \ud655\uc7a5\uc774 \uc608\uc0c1\ub429\ub2c8\ub2e4. \uce58\ub8cc \uc591\uc2dd\ubcc4\ub85c\ub294 PD-1\/PD-L1 \uccb4\ud06c\ud3ec\uc778\ud2b8 \uc5b5\uc81c\uc81c\uc758 \uad11\ubc94\uc704\ud55c \ucc44\ud0dd\uc5d0 \ud798\uc785\uc5b4 \uba74\uc5ed\uce58\ub8cc\uac00 2025\ub144 \ub9e4\ucd9c \uc810\uc720\uc728 37.25%\ub85c \uc2dc\uc7a5\uc744 \uc120\ub3c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc9c0\uc5ed\ubcc4\ub85c\ub294 \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc774 \uc758\ub8cc\ube44 \uc9c0\ucd9c \uc99d\uac00\uc640 \uaddc\uc81c \uc2b9\uc778 \uac00\uc18d\ud654\uc5d0 \ud798\uc785\uc5b4 2031\ub144\uae4c\uc9c0 12.23%\uc758 \uac00\uc7a5 \ube60\ub978 CAGR\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. \uc57d\ubb3c \uacc4\uc5f4 \uc911\uc5d0\uc11c\ub294 \ub2e4\uc218\uc758 FDA \ud601\uc2e0 \uce58\ub8cc\uc81c \uc9c0\uc815\uc5d0 \ub530\ub77c \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADC)\uac00 2031\ub144\uae4c\uc9c0 11.74%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uce21\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc5f0\uad6c \ubc29\ubc95\ub860 \ubc0f \uacbd\uc7c1 \ud658\uacbd:<br \/>\n\uc5f0\uad6c \ubc29\ubc95\ub860\uc740 \uc885\uc591 \uc804\ubb38\uc758, \ubcd1\uc6d0 \uc57d\uc0ac, \ubcf4\ud5d8 \uc804\ubb38\uac00 \ub4f1\uacfc\uc758 1\ucc28 \uc778\ud130\ubdf0\uc640 \uc138\uacc4\ubcf4\uac74\uae30\uad6c(WHO), \uc9c8\ubcd1\ud1b5\uc81c\uc608\ubc29\uc13c\ud130(CDC) \ub4f1 \ucd9c\ud310\ub41c \uc5ed\ud559 \ub370\uc774\ud130, FDA \ubc0f EMA \uc57d\ubb3c \uc2b9\uc778 \uc11c\ub958 \ub4f1\uc744 \ud65c\uc6a9\ud55c 2\ucc28 \uc5f0\uad6c\ub97c \uacb0\ud569\ud569\ub2c8\ub2e4. \uc2dc\uc7a5 \uaddc\ubaa8\ub294 \uc0c1\ud5a5\uc2dd(bottom-up) \ubc0f \ud558\ud5a5\uc2dd(top-down) \uc811\uadfc\ubc95\uc744 \ud1b5\ud574 \uc608\uce21\ub418\uba70, \ub370\uc774\ud130 \uac80\uc99d \ubc0f \uc5f0\uac04 \uc5c5\ub370\uc774\ud2b8 \uacfc\uc815\uc744 \uac70\uce69\ub2c8\ub2e4.<br \/>\n\uacbd\uc7c1 \ud658\uacbd \ubd84\uc11d\uc5d0\ub294 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4, \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d, \uadf8\ub9ac\uace0 \uc544\uc2a4\ud2b8\ub77c\uc81c\ub124\uce74, \uba38\ud06c, \ub85c\uc288, \ube0c\ub9ac\uc2a4\ud1a8 \ub9c8\uc774\uc5b4\uc2a4 \uc2a4\ud045 \ub4f1 \uc8fc\uc694 20\uac1c \uae30\uc5c5\uc758 \ud504\ub85c\ud544\uc774 \ud3ec\ud568\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uae30\ud68c \ubc0f \ubbf8\ub798 \uc804\ub9dd:<br \/>\n\ubcf4\uace0\uc11c\ub294 \ubbf8\uac1c\ucc99 \uc601\uc5ed(white-space) \ubc0f \ubbf8\ucda9\uc871 \uc218\uc694(unmet-need)\uc5d0 \ub300\ud55c \ud3c9\uac00\ub97c \ud1b5\ud574 \ud5a5\ud6c4 \uc2dc\uc7a5 \uae30\ud68c\uc640 \uc804\ub9dd\uc744 \uc81c\uc2dc\ud569\ub2c8\ub2e4.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-49553","post","type-post","status-publish","format-standard","hentry","category-market-reports"],"_links":{"self":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/49553"}],"collection":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/comments?post=49553"}],"version-history":[{"count":0,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/49553\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/media?parent=49553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/categories?post=49553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/tags?post=49553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}